



**BioLight Life Sciences Ltd.  
(The "Company")**

**16 February 2023**

**To:  
Israel Security Authority**

**[www.isa.goc.il](http://www.isa.goc.il)**

**TASE- Tel Aviv Stock Exchange  
[www.tase.co.il](http://www.tase.co.il)**

**Re: Investment agreement by an international corporation in Belkin Vision  
(Affiliated Company)**

The Company is hereby proud to announce that Belkin Vision Ltd. ("Belkin Vision"), a holding company of the Company, has informed it that it has completed a capital raising fund in the amount of \$12.6 Million U.S. Dollars in the form of a loan agreement convertible into Belkin Vision shares with an international corporation.

As of this date, the Company owns approximately 4% of the issued and paid-up share capital of Belkin Vision.

**About Belkin Vision**

Belkin Vision is engaged in the development of a laser device whose goal is to allow glaucoma patients to receive effective and short laser treatment as a primary treatment for the disease. As reported to the company, in May 2022 Belkin Vision received CE approval for the Eagle™ product under the new MDR directive

**About BioLight**

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.